Key facts
- It has raised $10.0M; the latest was Seed Round ($10.0M) in Mar 2026.
- Notable investors include Creative Destruction Lab, The Engine, VU Venture Partners, ACT Venture Partners, Brooks Hill Partners — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Cellbricks Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellbricks Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellbricks Therapeutics
Developer of a bio-fabrication platform intended to address the global challenge of organ shortage and the need for improved in-vitro models. The company's platform helps the industrial production of large and complex structures, seamlessly integrating different biomaterials and cell varieties, enabling medical researchers to provide their patients with improved clinical treatments.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Founded
- 2015
- Employees
- 30
- Website
- cellbricks-therapeutics.com/
- Ownership
- Privately Held (backing)
Cellbricks Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellbricks Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellbricks Therapeutics in its N-PORT filings yet. We sweep new filings monthly.